Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
USE OF ERIBULIN AND CYCLIN DEPENDENT KINASE INHIBITORS IN THE TREATMENT OF CANCER
Document Type and Number:
WIPO Patent Application WO/2019/017497
Kind Code:
A1
Abstract:
The invention features methods for treating and preventing cancer (e.g., an estrogen receptor-positive (ER+) breast cancer) in a patient in need thereof by administering eribulin (e.g., eribulin mesylate) in combination with a cyclin dependent kinase (CDK) inhibitor.

Inventors:
LITTLEFIELD BRUCE A (US)
HENDLER GARY (GB)
Application Number:
PCT/JP2018/027513
Publication Date:
January 24, 2019
Filing Date:
July 23, 2018
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
EISAI R&D MAN CO LTD (JP)
International Classes:
A61K31/357; A61K31/138; A61K31/4196; A61K31/506; A61K31/519; A61K31/565; A61K39/395; A61K45/00; A61P35/00; A61P35/02; A61P35/04; A61P43/00
Domestic Patent References:
WO2014087230A12014-06-12
WO2016141209A12016-09-09
Foreign References:
Other References:
DEAN, JEFFRY L. ET AL.: "Modification of the DNA Damage Response by Therapeutic CDK4/6 Inhibition", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 287, no. 34, 2012, pages 29075 - 29087, XP055563098, ISSN: 0021-9258
MORIKAWA, AKI ET AL.: "Palbociclib for the Treatment of Estrogen Receptor-Positive , HER2-Negative Metastatic Breast Cancer", CLINICAL CANCER RESEARCH, vol. 21, no. 16, 2015, pages 3591 - 3596, XP055563105, ISSN: 1078-0432
CLARK, AMY SANDERS ET AL.: "A phase I trial of palbociclib and paclitaxel in metastatic breast cancer", JOURNAL OF CLINICAL ONCOLOGY, vol. 32, no. 15, 2014, XP009519025, ISSN: 0732-183X, DOI: 10.1200/jco.2014.32.15_suppl.527J
SANCHEZ-MARTINEZ, CONCEPCION ET AL.: "Cyclin dependent kinase (CDK) inhibitors as anticancer drugs", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 25, no. 17, 2015, pages 3420 - 3435, XP029249423, ISSN: 0960-894X
TOWLE, MURRAY J. ET AL.: "Broad Spectrum Preclinical Antitumor Activity of Eribulin (Halaven): Optimal Effectiveness under Intermittent Dosing Conditions", ANTICANCER RESEARCH, vol. 32, no. 5, May 2012 (2012-05-01), pages 1611 - 1619, XP055563115, ISSN: 0250-7005
OHNO, SHINJI: "Tolerability of Therapies Recommended for the Treatment of Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer", CLINICAL BREAST CANCER, vol. 16, no. 4, August 2016 (2016-08-01), pages 238 - 246, XP055563117, ISSN: 1526-8209
HU , XICHUN ET AL.: "Emerging therapies for breast cancer", JOURNAL OF HEMATOLOGY & ONCOLOGY, vol. 10, no. 1, 28 April 2017 (2017-04-28), pages 1 - 17, XP055563120, ISSN: 1756-8722
NOMOTO, KENICHI ET AL.: "Abstract B191: Synergistic anticancer activity of eribulin plus palbociclib in patient-derived xenograft (PDX) models of ER+/Her2- human breast cancer", MOLECULAR CANCER THERAPEUTICS, vol. 17, no. 1, January 2018 (2018-01-01), XP055563128, ISSN: 1535-7163
RAO, SHREYAS S. ET AL.: "Synergistic effect of eribulin and CDK inhibition for the treatment of triple negative breast cancer", ONCOTARGET, vol. 8, no. 48, 10 August 2017 (2017-08-10), pages 83925 - 83939, XP055563133, ISSN: 1949-2553
ASANO, MAKOTO ET AL.: "Broad-spectrum Preclinical Antitumor Activity of Eribulin (Halaven): Combination with Anticancer Agents of Differing Mechanisms", ANTICANCER RESEARCH, vol. 38, no. 6, 2018, pages 3375 - 3385, XP055563137, ISSN: 0250-7005
See also references of EP 3654967A4
Attorney, Agent or Firm:
SK INTELLECTUAL PROPERTY LAW FIRM et al. (JP)
Download PDF: